| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
|
J Clin Oncol
|
2009
|
4.07
|
|
2
|
Active surveillance of small renal masses: progression patterns of early stage kidney cancer.
|
Eur Urol
|
2011
|
3.75
|
|
3
|
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer.
|
Eur Urol
|
2010
|
3.41
|
|
4
|
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
|
J Natl Cancer Inst
|
2005
|
2.99
|
|
5
|
A new and highly prognostic system to discern T1 bladder cancer substage.
|
Eur Urol
|
2011
|
2.68
|
|
6
|
Therapeutic options following orchiectomy for stage I seminoma.
|
Oncology (Williston Park)
|
2009
|
2.67
|
|
7
|
Evidence for a biopsy derived grade artifact among larger prostate glands.
|
J Urol
|
2006
|
2.23
|
|
8
|
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.
|
BJU Int
|
2010
|
2.14
|
|
9
|
Pharmacological approaches to reducing the risk of prostate cancer.
|
Eur Urol
|
2009
|
2.09
|
|
10
|
Longer wait times increase overall mortality in patients with bladder cancer.
|
J Urol
|
2009
|
2.05
|
|
11
|
Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.
|
J Urol
|
2010
|
1.87
|
|
12
|
Is there an optimal comorbidity index for prostate cancer?
|
Cancer
|
2008
|
1.80
|
|
13
|
Health information quality on the internet in urological oncology: a multilingual longitudinal evaluation.
|
Urology
|
2009
|
1.78
|
|
14
|
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens.
|
Am J Surg Pathol
|
2008
|
1.72
|
|
15
|
Population based survival data on urachal tumors.
|
J Urol
|
2006
|
1.55
|
|
16
|
Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
|
J Urol
|
2013
|
1.54
|
|
17
|
Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts.
|
J Natl Cancer Inst
|
2007
|
1.53
|
|
18
|
Optimal management of high-risk T1G3 bladder cancer: a decision analysis.
|
PLoS Med
|
2007
|
1.53
|
|
19
|
Higher surgeon and hospital volume improves long-term survival after radical cystectomy.
|
Cancer
|
2013
|
1.52
|
|
20
|
Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer.
|
Cancer
|
2009
|
1.50
|
|
21
|
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer.
|
BJU Int
|
2012
|
1.46
|
|
22
|
Pathological stage review is indicated in primary pT1 bladder cancer.
|
BJU Int
|
2009
|
1.46
|
|
23
|
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer.
|
J Clin Oncol
|
2010
|
1.45
|
|
24
|
Demographic analysis: an update of randomized controlled studies in prostatic oncology.
|
Can Urol Assoc J
|
2011
|
1.42
|
|
25
|
Radical prostatectomy in obese patients: Improved surgical outcomes in recent years.
|
Int J Urol
|
2010
|
1.41
|
|
26
|
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
|
Cancer
|
2007
|
1.35
|
|
27
|
Is there age bias in the treatment of localized prostate carcinoma?
|
Cancer
|
2004
|
1.29
|
|
28
|
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
|
Mod Pathol
|
2012
|
1.26
|
|
29
|
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression.
|
Int J Cancer
|
2011
|
1.25
|
|
30
|
Surgical margin status among men with organ-confined (pT2) prostate cancer: a population-based study.
|
Can Urol Assoc J
|
2011
|
1.17
|
|
31
|
The continuing importance of transrectal ultrasound identification of prostatic lesions.
|
J Urol
|
2007
|
1.16
|
|
32
|
Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines.
|
J Urol
|
2002
|
1.13
|
|
33
|
Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.
|
Eur Urol
|
2013
|
1.09
|
|
34
|
Urologists in cyberspace: A review of the quality of health information from American urologists' websites using three validated tools.
|
Can Urol Assoc J
|
2013
|
1.07
|
|
35
|
Laparoscopic lens fogging: a review of etiology and methods to maintain a clear visual field.
|
J Endourol
|
2010
|
1.07
|
|
36
|
Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines.
|
Cancer Res
|
2002
|
1.04
|
|
37
|
Antioxidants block prostate cancer in lady transgenic mice.
|
Cancer Res
|
2004
|
1.03
|
|
38
|
The FGFR3 mutation is related to favorable pT1 bladder cancer.
|
J Urol
|
2011
|
1.03
|
|
39
|
DNA methylation of HOXD3 as a marker of prostate cancer progression.
|
Lab Invest
|
2010
|
1.01
|
|
40
|
Nutraceuticals and prostate cancer prevention: a current review.
|
Nat Rev Urol
|
2009
|
1.00
|
|
41
|
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
|
Eur Urol
|
2012
|
1.00
|
|
42
|
Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy.
|
J Urol
|
2009
|
1.00
|
|
43
|
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
|
BJU Int
|
2011
|
0.98
|
|
44
|
A combination of micronutrients is beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady transgenic model.
|
Cancer Prev Res (Phila)
|
2009
|
0.96
|
|
45
|
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
|
Expert Rev Anticancer Ther
|
2008
|
0.94
|
|
46
|
Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer.
|
Eur Urol
|
2011
|
0.93
|
|
47
|
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
|
BJU Int
|
2012
|
0.91
|
|
48
|
The management of BCG failure in non-muscle-invasive bladder cancer: an update.
|
Can Urol Assoc J
|
2009
|
0.91
|
|
49
|
Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease.
|
J Urol
|
2002
|
0.90
|
|
50
|
Oral contraceptive use is associated with prostate cancer: an ecological study.
|
BMJ Open
|
2011
|
0.90
|
|
51
|
Varied definitions of hospital volume did not alter the conclusions of volume-outcome analyses.
|
J Clin Epidemiol
|
2008
|
0.89
|
|
52
|
Detection of urothelial tumors: comparison of urothelial phase with excretory phase CT urography--a prospective study.
|
Radiology
|
2012
|
0.89
|
|
53
|
An analysis of world media reporting of two recent large randomized prospective trials investigating screening for prostate cancer.
|
BJU Int
|
2011
|
0.88
|
|
54
|
Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer.
|
Nat Rev Clin Oncol
|
2010
|
0.88
|
|
55
|
An update on chemoprevention strategies in prostate cancer for 2006.
|
Curr Opin Urol
|
2006
|
0.88
|
|
56
|
Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.
|
Epigenetics
|
2012
|
0.88
|
|
57
|
MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer.
|
Clin Chem
|
2013
|
0.88
|
|
58
|
Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
|
J Urol
|
2010
|
0.85
|
|
59
|
Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.
|
BJU Int
|
2012
|
0.85
|
|
60
|
Results of high intensity focused ultrasound treatment of prostate cancer: early Canadian experience at a single center.
|
Can J Urol
|
2011
|
0.84
|
|
61
|
Recovery of erectile function after unilateral and bilateral cavernous nerve interposition grafting during radical pelvic surgery.
|
J Urol
|
2009
|
0.84
|
|
62
|
Prehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial.
|
BMC Surg
|
2014
|
0.80
|
|
63
|
Health-related quality of life following radical prostatectomy: long-term outcomes.
|
Qual Life Res
|
2014
|
0.80
|
|
64
|
FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer.
|
Virchows Arch
|
2014
|
0.79
|
|
65
|
Preoperative evaluation of the "hostile pelvis" in radical prostatectomy with computed tomographic pelvimetry.
|
BJU Int
|
2006
|
0.79
|
|
66
|
Dutasteride and active surveillance of low-risk prostate cancer.
|
Lancet
|
2012
|
0.79
|
|
67
|
Predicting prostate biopsy outcome: artificial neural networks and polychotomous regression are equivalent models.
|
Int Urol Nephrol
|
2010
|
0.79
|
|
68
|
Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression?
|
Urol Ann
|
2010
|
0.79
|
|
69
|
Lymph node assessment and lymphadenectomy in bladder cancer.
|
J Surg Oncol
|
2009
|
0.79
|
|
70
|
Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel.
|
Mol Cancer Ther
|
2008
|
0.78
|
|
71
|
Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer.
|
BJU Int
|
2011
|
0.77
|
|
72
|
Words of wisdom. Re: XMRV is present in malignant prostate epithelium and is associated with prostate cancer, especially high-grade tumors.
|
Eur Urol
|
2010
|
0.77
|
|
73
|
Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols.
|
World J Urol
|
2012
|
0.77
|
|
74
|
Does patient age affect survival after radical cystectomy?
|
BJU Int
|
2012
|
0.77
|
|
75
|
Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4.
|
BMC Cancer
|
2010
|
0.77
|
|
76
|
Capsaicin: a novel radio-sensitizing agent for prostate cancer.
|
Prostate
|
2014
|
0.77
|
|
77
|
The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate.
|
Prostate
|
2008
|
0.76
|
|
78
|
Systematic lateral prostate biopsy--are the benefits worth the costs?
|
J Urol
|
2008
|
0.75
|
|
79
|
Re: Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. A. S. Duffield, T. K. Lee, H. Miyamoto, H. B. Carter and J. I. Epstein. J Urol 2009; 182: 2274-2278.
|
J Urol
|
2010
|
0.75
|
|
80
|
A smoking cessation program as a resource for bladder cancer patients.
|
Can Urol Assoc J
|
2011
|
0.75
|
|
81
|
Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records.
|
J Am Med Inform Assoc
|
2011
|
0.75
|
|
82
|
Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors.
|
Urology
|
2002
|
0.75
|
|
83
|
Editorial comment.
|
Urology
|
2009
|
0.75
|
|
84
|
Urologic complications of composite resection following combined modality treatment of colorectal cancer.
|
Ann Surg Oncol
|
2009
|
0.75
|
|
85
|
Effect of healthcare provider characteristics on nodal yield at radical cystectomy.
|
Urology
|
2008
|
0.75
|
|
86
|
Exercise does not counteract the effects of a "westernized" diet on prostate cancer xenografts.
|
Prostate
|
2013
|
0.75
|
|
87
|
The association between patient age and prostate cancer stage and grade at diagnosis.
|
BJU Int
|
2004
|
0.75
|
|
88
|
Maximizing outcomes in genitourinary cancers across the treatment continuum.
|
BJU Int
|
2011
|
0.75
|
|
89
|
Pharmacotherapy for prostate cancer: the role of hormonal treatment.
|
Discov Med
|
2007
|
0.75
|